Project Grant F30CA301802
Award Date 12/17/25
Completion Date 9/1/29
Dollars Obligated $109K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Florida, USA
Similar Awards
- The Department of Defense's Military Medical Research and Development program (CFDA 12.420) has awarded a $708,100 Project Grant to the Dana-Farber Cancer Institute, Inc. (Dfci) to conduct research on "Overcoming Rebound Growth of Pediatric Low-Grade Glioas Following MAPK Pathway Inhibition." The grant, which runs from July 1, 2024 to June 30, 2026, will support Dfci's efforts to better understand the mechanisms driving recurrence of pediatric low-grade glioma brain tumors after...
- This federal Project Grant award for $659,325.00 was provided by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program. The grant supports research to understand the role of mutant IDH1 in glioma pathophysiology and immune response mechanisms. The research will use a novel murine glioma model developed by incorporating genetic lesions into neural progenitor cells using the...
- This Project Grant award for $616,710.00, provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports the Children's Research Institute in Washington, D.C. in designing effective adoptive immunotherapy for high-risk pediatric medulloblastoma. The research aims to develop a rational combination with MRI-guided focused ultrasound technology to enhance this innovative cancer treatment approach. The award period runs from August 1, 2024...
- The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $773,607 Project Grant under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) to The Johns Hopkins University. The grant supports the development of brain-penetrant, histone evicting anthracycline drugs for the treatment of diffuse midline glioma (DMG), an aggressive and incurable form of pediatric brain cancer. The researchers are working to develop novel anthracycline...
- This federal Project Grant award of $460,940 from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, supports research conducted by the University of Texas MD Anderson Cancer Center to investigate how genetic risk factors for glioma, a type of brain cancer, impact neurodevelopmental processes and potentially promote tumor formation. The research leverages human...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $686,979 to The Regents of the University of California, San Francisco (UCSF) to develop an integrated metabolic therapy and imaging strategy for diffuse midline gliomas (DMGs), a type of malignant brain tumor in children. The key objectives are to: Investigate how the H3K27M mutation that drives DMG tumorigenesis affects tumor cell metabolism and the tumor microenvironment. Determine...
- This federal Project Grant award of $456,414 from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) will support the development and clinical evaluation of B7-H3 chimeric antigen receptor (CAR) T cells for the treatment of diffuse intrinsic pontine glioma (DIPG) in children and young adults. The grant, awarded to Seattle Children's Research Institute, will fund a Phase 2 clinical trial to assess the efficacy and safety of repeatedly administering the B7-H3 CAR T cells...
- This Project Grant award of $134,574.00 from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) supports research to investigate mechanisms underlying brain tumor microenvironment-specific suppression of anti-tumor immunity mediated by aberrant epidermal growth factor receptor (EGFR) signaling in glioblastoma (GBM). The research leverages a novel EGFR-activated immunocompetent murine glioma model to determine the impact of aberrant EGFR signaling and tumor-programmed...
- This federal Project Grant award of $223,176, granted by the National Cancer Institute under the Cancer Research Manpower program (CFDA 93.398), will fund research to investigate the role of SMARCAL1 depletion in promoting increased immunogenicity in alternative lengthening of telomeres (ALT)-positive high-grade gliomas. The overarching goal is to examine how therapeutic targeting of SMARCAL1, an annealing helicase, can lead to tumor-specific DNA damage, inflammation, and an enhanced immune...
- This Project Grant award from the National Institutes of Health's (NIH) National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $901,205 to The Children's Hospital Corporation (doing business as Boston Children's Hospital) to conduct genome-wide studies examining how tumor immune editing in early-stage cancers leads to immune evasion and suppression. The research aims to identify key genes, pathways, and processes that are epigenetically repressed during early tumor...